Stable Disease without Tumor Shrink Cannot Benefit from Surgery following Immune-Based Therapy in Potentially Resectable Hepatocellular Carcinoma

DpR is an important factor in choosing the right candidates and the timing of conversion therapy. Patients only at a DpR <0% receiving various immune-based treatments who met the "potentially resectable" criteria can benefit from surgical resection. These findings can help increase the success rate of conversion therapy in patients with advanced HCC.

Authors

Institutions

Publication Details

Journal
Liver Cancer
Published
2026-01-19
DOI
https://doi.org/10.1159/000550497
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Stable Disease without Tumor Shrink Cannot Benefit from Surgery following Immune-Based Therapy in Potentially Resectable Hepatocellular Carcinoma

Lu-Na Wang, HUI-CHUAN SUN, Huan-Chen Shi, Ying-Hao Shen et al.
Liver Cancer
Hepatocellular Carcinoma Treatment and Prognosis
article

Stable Disease without Tumor Shrink Cannot Benefit from Surgery following Immune-Based Therapy in Potentially Resectable Hepatocellular Carcinoma

Lu-Na Wang, HUI-CHUAN SUN, Huan-Chen Shi, Ying-Hao Shen, Shi-Qi Zhou, Cheng-Jie Zhong, Cheng Huang, Hui Li, Tian He, Zi-Yue Yang, Bin Xu, Xiao-Dong Zhu, Bo Hu, Jia Fan, Jian Zhou, Zi-Yi Wang, Qiang Gao
article en

Abstract

DpR is an important factor in choosing the right candidates and the timing of conversion therapy. Patients only at a DpR <0% receiving various immune-based treatments who met the "potentially resectable" criteria can benefit from surgical resection. These findings can help increase the success rate of conversion therapy in patients with advanced HCC.

Liver Cancer
Fudan University (CN), Zhongshan Hospital (CN)
Beijing Xisike Clinical Oncology Research Foundation, National Natural Science Foundation of China, Fudan University, National Science and Technology Major Project, Horizon 2020 Framework Programme, Bijzonder Onderzoeksfonds UGent
Good health and well-being
Openalex Percentile: Top 83%
Hepatocellular Carcinoma Treatment and Prognosis
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Stable Disease without Tumor Shrink Cannot Benefit from Surgery following Immune-Based Therapy in Potentially Resectable Hepatocellular Carcinoma — Lu-Na Wang, HUI-CHUAN SUN, et al. · Liver Cancer (2026) | TGRS Research Map | TGRS